LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
NEW YORK, Sept. 19, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased CytRx Corporation (NASDAQ:CYTR) securities between November 18, 2014 and July 11, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/cytrx-corporation. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts including: (1) that the clinical hold placed on the Phase 3 trial of aldoxorubicin for soft tissue sarcomas (“STSs”) would prevent sufficient follow-up for patients involved in the study; (2) that, as a result, nearly half of all patients would be excluded from the data since the study was disturbed by a partial clinical hold; (3) that, in response, CytRx would likely conduct a second analysis; (4) that, as such, the results of the trial could be materially affected and/or approval of aldoxorubicin for STS could be delayed; and (5) that, as a result of the foregoing, Defendants’ statements about CytRx’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
If you suffered a loss in CytRx you have until September 23, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/cytrx-corporation.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
